Quantitative characterization of UDP-glucuronosyltransferase 2B17 in human liver and intestine and its role in testosterone first-pass metabolism
Protein abundance and activity of UGT2B17, a highly variable drug- and androgen-metabolizing enzyme, was quantified in microsomes, S9, and primary cells isolated from human liver and intestine by a validated LC-MS/MS methods. UGT2B17 protein abundance showed >160-fold variation (mean \xc2\xb1 SD, 1.7 \xc2\xb1 2.7 pmol/mg microsomal protein) in adult human liver microsomes (n=26) and significant correlation (r2= 0.77, p<0.001) with TG formation. Primary role of UGT2B17 in TG formation compared to UGT2B15 was confirmed by performing the activity assay in UGT2B17 gene deletion samples and with a selective UGT2B17 inhibitor, imatinib. Human intestinal microsomes isolated from small intestine (n=6) showed on average significantly higher protein abundance (7.4 \xc2\xb1 6.6 pmol/mg microsomal protein, p=0.016) compared to liver microsomes, with an increasing trend towards distal segments of gastrointestinal (GI) tract. Commercially available pooled microsomes and S9 fractions confirmed greater abundance and activity of UGT2B17 in intestinal fractions compared to liver fractions. To further investigate the quantitative role of UGT2B17 in testosterone metabolism in whole cell system, a targeted metabolomics study was performed in hepatocytes (n=5), and enterocytes (n=16). TG was the second most abundant metabolite after androstenedione in both cell systems. Reasonable correlation between UGT2B17 abundance and activity were observed enterocytes (r2=0.69, p=0.003), but not in hepatocytes. These observational and mechanistic data will be useful in developing a physiologically-based pharmacokinetic (PBPK) model for predicting highly-variable first-pass metabolism of testosterone and other UGT2B17 substrates.
1. Introduction<!>2.1. Chemicals and reagents<!>2.2. Procurement of human liver and intestinal cells and subcellular fractions<!>2.3. Microsome isolation from donor-matched intestinal sections<!>2.4. Membrane protein extraction from primary cells and total protein quantification<!>2.5. Protein denaturation, reduction, alkylation, enrichment and trypsin digestion<!>2.6. Quantification of Surrogate peptides of UGT2B17 and UGT2B15 in subcellular fractions<!>2.7. Testosterone glucuronidation assay in subcellular fractions<!>2.8. Inhibition of UGT2B17 activity by tyrosine kinase inhibitors in HLM<!>2.9. Testosterone metabolism in human hepatocytes and enterocytes<!>2.10. LC-MS/MS analysis of testosterone metabolites formed in human hepatocytes and enterocytes<!>2.11.1. Fractional contribution of UGT2B17 in testosterone metabolism in HLM<!>2.11.2. Determination of UGT kinetic parameters<!>2.11.3. IC50 calculation for imatinib<!>2.12. Statistical Analysis<!>3.1. UGT2B17 and UGT2B15 abundance and correlation with testosterone glucuronidation in human liver and intestinal subcellular fractions<!>3.2. Enzyme kinetic parameters for testosterone in HLM<!>3.3. Inhibition of UGT2B17 and UGT2B15 by Tyrosine Kinase Inhibitors<!>3.4. UGT2B17 and UGT2B15 protein abundance and testosterone metabolism in primary human hepatocytes and enterocytes<!>4. Discussion
<p>UGT2B17 is highly variable in its abundance and is one of the most commonly deleted genes in humans, with a higher deletion frequency seen in Asians [1]. Recently, we have shown that other than copy number variation (CNV), multiple factors contribute to its variability, including sex, age, and single nucleotide polymorphisms [2]. In addition to variable pharmacokinetics (PK) and efficacy or toxicity of drugs (e.g. vorinostat) [3], drug metabolites (e.g., 17-dihydroexemestane) [4], and tobacco carcinogen (NNAL) [5], UGT2B17 variability has been associated with various testosterone-related clinical outcomes [6–13]. For example, studies show that UGT2B17 deletion individuals have 15% higher serum testosterone levels [6] and up to 90% lower urinary excretion of conjugated plus unconjugated testosterone [7]. UGT2B17 gene deletion is well recognized as major confounder for anti-doping tests in athletes that can produce false positive and negative results [8], and is also associated with lower body mass index in males in a sex-specific manner [9,10]. Similarly, although controversial [11], a genome-wide CNV study found a strong link between UGT2B17 deletion and lower osteoporosis risk [6]. In addition, recent meta-analyses show increased prostate cancer risk with UGT2B17 gene deletion, amidst conflicting results [12,13].</p><p>Testosterone levels decline steadily after age thirty, reaching hypogonadal levels in approximately 20% to 50% of men in their 60s and 80s, respectively [14]. Symptomatic hypogonadism is treated with exogenous administration of testosterone, which leads to improvements in fatigue, muscle strength, body mass index, and mood [15]. In 2011 alone, 3.8% of men in their 60s were on testosterone replacement therapy (TRT). TRT is available in the United States (US) in various forms, i.e., transdermal, intramuscular, nasal, buccal, and subdermal. Oral formulations approved in the US are prodrug formulations alkylated testosterone which accompanies increased risks of hepatotoxicity such as cholestatic jaundice, therefore limiting its use [16,17]. , Esterified prodrug testosterone undecanoate has been used in Canada [18] and in Europe since 1970s without risk of liver damage [19]. However, it requires co-consumption with a fatty meal due to its lymphatic absorption and has potential concerns regarding elevated dihydrotestosterone (DHT) levels [20,21]. Despite advantages of greater patient adherence and ease of use, oral testosterone formulations have been generally unsuccessful due to significant first-pass metabolism [15,20,22].</p><p>To develop a viable oral testosterone formulation, it is important to characterize factors responsible for its low and variable absolute bioavailability (3.6 ± 2.5 %) [23]. Intravenous testosterone is rapidly eliminated with a half-life ranging from 10 to 100 minutes with majority of testosterone excreted as glucuronide conjugates (up to 80%), suggesting extensive involvement of hepatic UGTs [24]. UGT2B17 and UGT2B15 are the major and minor isoforms responsible for TG formation, respectively [25], both of which are expressed in the liver. Moreover, UGT2B17 is also expressed in the intestine [26]. While these data indicate importance of UGT2B17 in testosterone first-pass metabolism, the quantitative role of intestinal and hepatic UGT2B17 has not been elucidated. Therefore, we first examined the abundance and testosterone glucuronidation activity of UGT2B17 and UGT2B15 in adult human liver and intestinal subcellular fractions. These data are important for physiologically-based PK (PBPK) modeling of first-pass metabolism of UGT2B17 substrates.</p><p>Testosterone also undergoes metabolism by several other enzymes such as steroid 5 alpha-reductase 2 (SRD5A2), cytochrome P450 3A4 (CYP3A4), 17β-hydroxysteroid dehydrogenase 2 (17βHSD2), and sulfotransferase 2A1 (SULT2A1) [27]. Particularly, CYP3A4, 17βHSD2, and SULT2A1 are expressed both in liver and intestine [28–31]. Our recent clinical study confirmed high circulating levels of glucuronides of androsterone, testosterone and eticholanolone after oral administration of testosterone [32]. However, individual contributions of liver and intestine in formation of these metabolites and their relative significance have not been studied to date. We therefore investigated quantitative metabolite profiling in human hepatocytes and enterocytes after testosterone incubation. Characterization of UGT2B17 contribution and testosterone glucuronidation in the first-pass organs may lead to opportunities in improved and precise oral TRT regimens that may mitigate risks and maximize benefits.</p><!><p>Testosterone, alamethicin, UDP-glucuronic acid (UDPGA), magnesium chloride, dibasic and monobasic potassium phosphate were purchased from Sigma-Aldrich (St. Louis, MO). Oxazepam was purchased from Fischer Scientific (Fair Lawn, NJ), and tyrosine kinase inhibitors (TKIs) were kindly provided by Genentech (San Francisco, CA). Testosterone metabolites, respective conjugates, and standards were purchased from Cerilliant Corporation (Round Rock, TX) and Steraloid (Newport, RI). Bovine serum albumin (BSA) and protein extraction reagents were obtained from Thermo Fisher Scientific (Rockford, IL). Protein quantification chemicals and reagents were obtained as previously reported [33]. Hepatocyte thawing (MCHT50) and incubation (MM250) media were obtained from Lonza (Durham, NC), whereas, enterocytes thawing (CERM) and incubation (HQM) media were from IVAL (Columbia, MD). Synthetic light (with amino acid analysis) and heavy labeled peptides were purchased from New England Peptides (Boston, MA) and Thermo Fisher Scientific (Rockford, IL), respectively.</p><!><p>Cryopreserved primary human hepatocytes (n=5) and enterocytes (n=16) were obtained from Lonza (Durham, NC) and IVAL (Columbia, MD), respectively. Pooled human microsomes (HLM), intestinal microsomes (HIM), liver S9 and intestinal S9 fractions were obtained from Xenotech (Kansas City, KS). HLMs (n=26) from individual donors were procured from the University of Washington School of Pharmacy Liver Bank (Seattle, WA) with institutional review board (IRB) reviewed to be exempt from further IRB-approval. Proteomics, activity, and genotyping data were previously published [2]; a subset of adult samples were used for reproduction at differing concentrations of testosterone . Donor-matched intestinal tissue segments (n=6) were procured from Pomeranian Medical University, Szczecin, Poland, and approved by the local Bioethics Committee. Sample demographics are described in Table 1.</p><!><p>Donor-matched HIMs were isolated from different sections of intestine, i.e., duodenum (D), jejunum (J1–J3, three sections), ileum (I), and colon (C), from six individual donors. Tissue samples were disrupted using cell crusher paddles in liquid-nitrogen and HIMs were isolated using protocols from Microsome isolation kit (Abcam, Cambridge, United Kingdom) described elsewhere [34]. Total protein was determined by bicinchoninic acid (BCA) assay using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Rockford, IL) per manufacturer's protocol.</p><!><p>Membrane proteins were extracted from the cells using Mem-PER Plus Membrane Protein Extraction kit protocol (Rockford, IL). Briefly, previously washed and frozen hepatocytes (0.7 to 6 million) and enterocytes (6.7–37 million) were resuspended with permeabilization buffer (200 or 400 μL), gently mixed, and incubated on a Compact Digital Waving Rotator (Thermo Fisher Scientific, Rockford, IL) for 30 minutes (4°C) at 300 rpm. Permeabilized cells were centrifuged at 16,000g for 15 minutes (4°C), and resulting supernatant containing cytosolic proteins was removed. Remaining pellet was resuspended with equivolume solubilization buffer, gently mixed, incubated for 60 minutes at 300 rpm (4°C), and centrifuged at 16,000g for 15 minutes (4°C). Resulting supernatant containing membrane proteins was collected and total protein quantification was measured with BCA assay (Thermo Fisher Scientific, Rockford, IL). Remaining solubilized membrane fraction was stored at −80°C for subsequent digestion and LC-MS/MS analysis.</p><!><p>Trypsin digestion was performed as previously described [33] for HLM and cell membrane samples. In brief, 10 μL dithiothreitol (250 mM), 30 μL ammonium bicarbonate buffer (100 mM, pH 7.8), 20 μL BSA (0.02 mg/mL), and 10 μL human serum albumin (10 mg/mL) were added to 80 μL samples (≤ 2 mg/mL total protein), followed by heat denaturation and reduction for 10 minutes at 95°C. Upon cooling to room temperature, alkylation was performed by addition of 20 μL iodoacetamide (500 mM) and incubation in room temperature (in dark) for 30 minutes. Protein enrichment and desalting was done with extraction using chloroform-methanol-water (1:5:4) and resulting pellet washed and resuspended in 60 μL ammonium bicarbonate buffer (50 mM, pH 7.8). Trypsin (0.16 μg/μL) was added for digestion for 16 hours at 300 rpm (37°C). Digestion was quenched on dry ice with addition of 20 μL of heavy peptide internal standard cocktail and 10 μl acetonitrile: water 80:20 (v/v) with 0.5% formic acid. After centrifugation at 4000g for 5 minutes (4°C), resulting supernatant was analyzed by LC-MS/MS method.</p><p>UGT2B17 quantification in donor-matched individual HIMs was performed at a different site (Oswald lab, University of Greifswald, Greifswald, Germany) using a slightly different method. The differences include trypsin digestion by filter-aided sample preparation (FASP) protocol and the use of ProteaseMax (Promega, Madison, WI) as a surfactant as discussed in detail elsewhere [35]. Three quality control HLM samples previously characterized for UGT2B17 abundance using method described above were used as quality controls for FASP protocol to address inter-laboratory technical variability.</p><!><p>HLM, S9 fractions, and hepatocyte cell membranes were analyzed using Sciex Triple Quadrupole 6500 system (Sciex, Framingham, MA) coupled to Acquity UPLC System (Waters Technologies, Milford, MA). Chromatographic separation of peptides was achieved on ACQUITY UPLC HSS T3 1.8 μm, C18 100A; 100 × 2.1 mm (Waters, Milford, MA) column. Skyline and Analyst 1.6.2 software were used to process acquired LC-MS/MS data. Detailed LC-MS/MS parameters have been previously published [2]. To address technical variability, we used heavy peptide internal standard as well as BSA for exogenous protein standard for all samples except enterocytes due to preexistence of BSA.</p><p>For donor-matched HIMs and three quality control samples digested using FASP protocol, LC-MS/MS analysis was performed using Kinetex C18 reverse phase column (100 x 2.1 mm, Phenomenex, Torrance, CA) and AB Sciex QTRAP 5500 system (Sciex, Framingham, MA). Data analysis was done using MultiQuant 3.0.2 software (Sciex, Framingham, MA). As individual HIM samples were quantified using FASP protocol, three HLM samples representing deletion, mid and high UGT2B17 abundance were used as quality controls and calibrators to address any technical variability.</p><!><p>Testosterone glucuronidation assay was performed in individual and pooled microsomes and S9 fractions except donor-matched HIMs due to limited samples. Assays were performed in triplicates with 10 μg of protein in 5 mM MgCl2 and 100 mM potassium phosphate buffer (pH 7.4), 0.01% BSA, and 0.1 mg/mL of alamethicin in 100 μL final volume with testosterone (50 nM to 5 μM). After 15 minutes of pretreatment on ice, reactions were initiated by addition of 2.5 mM UDP-glucuronic acid (UDPGA), incubated for 30 minutes (37°C) at 300 rpm, and terminated using 200 μL of ice-cold acetonitrile containing deuterated TG or rosuvastatin as validated internal standards. Samples were centrifuged at 10,000g for 5 minutes (4°C). TG (Table 2) and rosuvastatin (m/z 482.1→258.2; DP 70; CE 40) were quantified in supernatant by LC-MS/MS. Enzyme kinetic parameters (Vmax and Km) were determined for UGT2B17 using three HLMs with high, mid, or null UGT2B17 abundance (9.7, 2.3, and 0.06 pmol/mg microsomal protein, respectively) with comparable UGT2B15 abundance (27, 20, and 34 pmol/mg microsomal protein, respectively). Assays were performed in triplicates with varying testosterone concentrations (0.05, 0.25, 0.5, 2.5, 5, 10, 15, 25 μM) and closely followed the protocol for testosterone glucuronidation assay.</p><!><p>UGT2B17 inhibition assays were performed on two HLMs expressing high and below limit of detection (LOD) UGT2B17 abundance (9.7 and 0.06 pmol/mg microsomal protein) with comparable UGT2B15 abundance (27 and 24 pmol/mg microsomal protein). Inhibition assays were performed in triplicates and followed the testosterone glucuronidation assay. One and 25 μM of various TKIs (gefitinib, lapatinib, pazopanib, sorafenib, sunitinib, sirolimus, temsirolimus, dasatinib, nilotinib, and imatinib) were preincubated for 5 minutes at 37°C prior to reaction initiation with UDPGA with 5 μM testosterone to screen for UGT2B17 specificity. The most potent and selective UGT2B17 inhibitor imatinib was further assayed for IC50 determination with varying imatinib concentrations (0.01, 0.02, 0.05, 0.1, 0.5, 1, 10, 50, and 100 μM). UGT2B17 activity was measured with TG formation with 1 μM testosterone. Oxazepam was used as a probe substrate for UGT2B15 activity by measuring oxazepam glucuronide formation (m/z 463.3→287.1, 269.1; DP 70; CE 20) with 10 μM oxazepam.</p><!><p>Hepatocytes (n=5) were thawed for 90 to 120 seconds in 37°C waterbath, resuspended in 15 mL of MCHT50, and centrifuged at 100g for 8 minutes at room temperature. Cell count was performed using Nexcelom Bioscience Cellometer Auto T4 (Lawrence, MA), followed by a second centrifugation at 100g for 1 minute. Cells were then resuspended in MM250 at 1 million cells per mL concentration and preincubated for 10 minutes at 37°C. Reactions were initiated by adding 500 μL of hepatocyte suspension to 500 μL pre-warmed MM250 containing 100 μM Testosterone in 12-well plates. Final 1 mL mixture in each well contained 0.5 million cells in 50 μM Testosterone, which was incubated for 60 minutes (37°C) at 100 rpm. Total organic solvent (v/v) did not exceed 0.1%. Incubation was terminated by addition of 2 mL ice-cold acetonitrile containing internal standards. Cells were mechanically lysed by vortex mixing and centrifugation at 3000g for 10 minutes (4°C). Supernatant was immediately stored at −80°C prior to analysis by LC-MS/MS. Enterocytes (n=16) followed a similar protocol using CERM and HQM as thawing and incubation media, respectively, and were seeded to yield a final 100 μL mixture in 96-well plate containing up to 150,000 cells in 50 μM Testosterone followed by a 120-minute incubation (37°C) at 100 rpm.</p><!><p>Testosterone and its metabolites (Table 2) were measured by LC-MS/MS using the same system as protein quantification. Quantified metabolites include testosterone glucuronide (TG), 5α-dihydrotestosterone (DHT), DHT glucuronide (DHTG), androsterone (A), androsterone glucuronide (AG), androstenedione (AED), 6-hydroxy testosterone (6OHT), eticholanolone (E), and eticholanolone glucuronide (EG). LC conditions were set at 0.3 mL/min flow rate and 5 μL injection volume with mobile phase A: water with 0.1% formic acid and B: acetonitrile with 0.1% formic acid. The gradient program was: 85% A (0–2.5 min), 85-60% (2.5–8.5 min), 60-50% (8.5–12.8 min), 50-2% (12.8–13 min), 2–85% (13–15 min). Whenever available, deuterated internal standards were used. Lower limit of quantification (LLOQ) was established, with limit of detection (LOD) set as one-third of LLOQ values. Multiple reaction monitoring (MRM) parameters used to quantify testosterone metabolites are shown in Table 2.</p><!><p>Fractional contribution (fm) of UGT2B17 was calculated using Equation 1 through 3. We assumed thatactivity measured by TG formation (CL) is mediated only by UGT2B17 and UGT2B15. Thus all TG formation was via UGT2B15 in homozygous UGT2B17 gene deletion samples (UGT2B17 del-del). Normalized average UGT2B15 activity was calculated as the average activity in these samples divided by their average UGT2B15 protein expression (Equation 1). We then obtained individual UGT2B15 activity by multiplying average UGT2B15 activity with individual UGT2B15 protein abundance. This value is subtracted from total individual activity (CLtotal obs) to acquire individual UGT2B17 activity (CLUGT2B17) (Equation 2). Individual UGT2B15 and UGT2B17 fm are the respective individual activities divided by total individual TG formation (Equation 3). Negative estimates of UGT2B17 activity were adjusted to zero. Calculations were performed using Microsoft Excel (Redmond, WA).</p><!><p>Enzyme kinetic parameters (Km and Vmax) were obtained by fitting the Michaelis-Menten equation using GraphPad Prism version 5.03 for Windows (La Jolla, CA) (Equation 4), where Y is testosterone glucuronidation rate (pmol/mg protein/min) and X is testosterone concentration (μM).</p><!><p>IC50 values were calculated using the following nonlinear regression model (Equation 5), where Y is relative glucuronidation activity (% TG formation) and X is inhibitor concentration (μM). IC50 values were obtained using GraphPad Prism version 5.03 for Windows (La Jolla, CA).</p><!><p>UGT2B217 protein abundance between HLM and HIM (excluding colon) was compared using Mann-Whitney test. UGT2B17 protein abundance-TG formation correlation and corresponding p-values were obtained using Spearman's correlation. Statistical analyses were performed with GraphPad Prism version 5.03 for Windows (La Jolla, CA).</p><!><p>Protein abundance in adult HLMs (n=26) showed high inter-individual variability for UGT2B17 (>160-fold) with 46% (n=12) falling below LLOQ, which included 23% confirmed gene deletions (n=6) (Table 3), while UGT2B15 protein abundance was much less variable (4-fold) (Figure 1A). High variability in UGT2B17 was also observed in HIMs (>492-fold), with an increasing trend observed down the gastrointestinal (GI) segments (Figure 1C). Average UGT2B17 protein abundance in the HIM (excluding colon) was significantly higher (4.4-fold) than HLM (p=0.016). UGT2B15 was not detectable in donor-matched HIMs and pooled fractions, in agreement with published literature [26,35,36]. . UGT2B17 protein abundance in individual HLM showed a strong correlation with testosterone glucuronidation activity (r2= 0.77, p<0.001) (Figure 1E), confirming its major role in TG formation. UGT2B15 showed a significant correlation with TG formation only in samples with UGT2B17 level below LLOQ (r2=0.65, p=0.02) (Figure 1F), consistent with our previous findings [2]. In addition, UGT2B17 abundance and TG formation was higher in pooled subcellular fractions from intestine compared to liver (Figure 1F). Estimated fractional contribution for UGT2B17 (fm,UGT2B17) and UGT2B15 (fm,UGT2B15) ranged from 0 to 0.91, and 0.09 to 1, respectively, depending on UGT2B17 variability (Figure 1B). For example, fm,UGT2B17 was 0.74 or higher in samples with UGT2B17 abundance >1 pmol/mg microsomal protein, whereas, fm,UGT2B15 was 0.85 or higher in samples that were below LLOQ for UGT2B17.</p><!><p>Calculated Km (μM) and Vmax (pmol/mg protein/min) for high, mid, and null UGT2B17-expressing HLMs were 13.5, 4.0, and 8.1 μM, and 5.96, 1.44, and 0.295 nmol/mg protein/min, respectively (Figure 2A). High and mid UGT2B17-expressing HLMs had a 4-fold difference in absolute UGT2B17 protein abundance (9.6 and 2.3 pmol/mg protein, respectively) with a corresponding 4-fold difference in calculated Vmax. Noticeable substrate depletion was observed for high UGT2B17 expressing HLM at low and mid testosterone concentration ranges, perhaps leading to variability observed in Km values.</p><!><p>Among the 10 TKIs screened for UGT2B17 inhibition, imatinib was the most potent and selective inhibitor for UGT2B17 (Figure 2D). IC50 values for imatinib using testosterone as a substrate was 0.31 μM for high-UGT2B17 expressing HLM and 69 μM for low-UGT2B17 expressing HLM (Figure 2B), with the lower value being in agreement with published literature for recombinant UGT2B17 [37]. When oxazepam was used as a probe substrate for UGT2B15, imatinib IC50 values in high- and low-UGT2B17 expressing HLM were similar with mean values of 54 μM and 79 μM, respectively (Figure 2C).</p><!><p>In hepatocytes, protein abundance (mean ± SD, pmol/mg membrane protein) for UGT2B17 and UGT2B15 were 0.4 ± 0.4 and 6.5 ± 4.3, respectively. In enterocytes, UGT2B17 protein abundance (mean ± SD, fmol/million cells) was 11.8 ± 12.6 and UGT2B15 was not detected.</p><p>Structures of quantified testosterone metabolites with corresponding enzymes in a simplified metabolism scheme are shown in Figure 3A, with respective metabolite formation rates of each metabolite listed in Table 4. A representative chromatogram of a hepatocyte incubation showing chromatographic and MS/MS separation is shown in Figure 3B. The three most abundant metabolites were AED, TG, and 6OH for both hepatocytes and enterocytes, whereas, DHT, DHTG, A, and AG combined constituted less than 4% (hepatocytes) and 1% (enterocytes), and E and EG were below LLOQ (Figures 4A, 4C). TG was the second major metabolite measured, at two-fold or higher abundance levels compared to other metabolites except AED. TG formation rate (mean ± SD, pmol/million cells/hour) was higher in hepatocytes (4836 ± 2460) compared to enterocytes (437 ± 433). Correlation between relative UGT2B17 protein abundance and TG formation was significant in enterocytes (r2=0.68, p=0.004). However, the correlation was not significant in hepatocytes, perhaps due to smaller sample size and confounding role of UGT2B15 (Figures 4B, 4D). UGT2B15 also showed nonsignificant correlation with TG formation in hepatocytes and was not detected in enterocytes.</p><!><p>To the best of our knowledge, this is the first study to demonstrate regional distribution of UGT2B17 in paired intestinal microsomes. It is also the first to apply a primary enterocyte model to study testosterone metabolomics and UGT activity in enterocytes in comparison with hepatocytes. Here we also propose a facile method of fm estimation for UGT2B17 substrates in HLMs using gene deletion samples when two or more UGT isoforms are involved in glucuronidation.</p><p>UGT2B17 protein abundance in subcellular fractions revealed two findings with notable implications. First, UGT2B17 showed 4.4-fold higher abundance in intestine compared to liver, in agreement with published literature reporting two-fold higher levels of UGT2B17 in intestine [26]. The same article reports UGT2B17 constituting 3% of total UGT isoforms in the liver but 59% in the intestine, in contrast to UGT2B15 which has high relative hepatic expression of 12% but was undetected in intestine, similar to our findings. Again in contrast to UGT2B17, UGT2B7, which is considered to be a major drug-metabolizing UGT isoform [38], constitutes 22% and 4% of total UGT isoforms in the liver and intestine, respectively [26]. This unique expression of UGT2B17 augments the clinical significance of first pass metabolism for orally administered UGT2B17 substrates. Bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping intestinal metabolism (Fg), and fraction escaping hepatic metabolism (Fh). In general, intestinal metabolism is considered to be equal to or lower than liver due to lower DME expression and activity in the GI wall [28,39,40]. However, for UGT2B17 substrates, significantly greater intestinal metabolism may occur relative to other UGTs, resulting in lower Fg than Fh, leading to a highly variable first-pass effect with less variable systemic clearance. An example of this is MK-7246, which was discontinued from development due to unexpected PK variability. This was later attributed to UGT2B17, showing a 25-fold higher area under the curve in subjects with UGT2B17 gene deletion [41]. Secondly, UGT2B17 showed an increasing trend down the GI tract from duodenum to colon. This indicates that the site of absorption may impact the extent of UGT2B17-mediated GI metabolism (Fg), which can potential contribute to significant variability in drug disposition due to factors affecting GI motility and transit time and may also be viable for targeted drug delivery. It also brings in likelihood of variability in drug disposition by affecting the extent of enterohepatic recycling. On the other hand, UGT2B15 showed relatively consistent expression in the liver and was undetected in pooled intestinal subcellular fractions and cells. This supports the absence of UGT2B15 in intestinal tissues, where literature reports detection at mRNA levels and inconsistency at protein levels [26,36,42].</p><p>Considering the higher expression of UGT2B17 in HIM, it is reasonable to expect more TG formation in enterocytes compared to hepatocytes. However, enterocytes showed an overall 10-fold lower activity, despite the metabolome profile being reflective of hepatocytes. This is possibly due to lower soluble protein content of enterocytes and loss of activity during cryopreservation of enterocytes. There have been two published studies reporting cryopreserved enterocyte activities [43,44] and further characterization would be beneficial.</p><p>The estimation method for fractional contribution is applicable to other polymorphic enzymes such as CYP2D6. The wide range of fm,UGT2B17 from 0 to 0.91 shows variable DDI potentials for UGT2B17-specific substrates, which is highlighted by imatinib as a potent UGT2B17-specific inhibitor. Imatinib IC50 value of 0.3 μM, combined with calculated maximum unbound hepatic input concentration of 0.7 μM [37], can lead to double the exposure of a UGT2B17-specific substrate. However, the magnitude of imatinib inhibition will vary widely depending on UGT2B17 protein abundance levels thus fm,UGT2B17. For the subset of high UGT2B17-expressors, potential DDIs become particularly concerning, where UGT2B17 inhibition will lead to dramatic increase in its substrate. However, identification of these high-expressors cannot easily be done, as genotype, age, sex, and SNP combined accounts for only 29% of UGT2B17 variability [2]. Thus, identifying a phenotypic biomarker or probe drug for UGT2B17 would be beneficial in identifying these individuals at high risk for DDI.</p><p>Androstenedione (AED), rather than TG as a major metabolite in both hepatocytes and enterocytes is an unexpected, albeit reasonable finding. 17 β-HSD2 mediates AED formation from testosterone, while 17 β-HSD1,17 β-HSD3, and 17 β-HSD5 convert AED to testosterone [29]. 17 β-HSD2 has high expression in GI and liver, while 17 β-HSD1 and 17 β-HSD3 are sex tissue-specific, and 17 β-HSD5 is ubiquitously expressed [45,46]. AED is one of the main adrenal hormones in circulation along with DHEA as an inactive adrenal precursor. AED as a reservoir pool explains the preferential AED formation over elimination via glucuronidation pathway at supra-physiological testosterone concentrations in a limited timeframe.</p><p>Figure 5 shows the average plasma metabolite profile in seven healthy adult men at baseline (Figure 5A), following an 800mg oral testosterone administration up to 24 hours after chemical castration with acyline (Figure 5B), and the fold-difference from baseline (Figure 5C) from a previously published study [32]. TG had the most significant increase in percentage and absolute concentration (10-fold and 280-fold, respectively), compared to the next highest increase seen in DHTG and EG (both about 1.5-fold and 40-fold, respectively). This indicates the important role of glucuronidation in exogenous testosterone elimination, which may have been attenuated by AED formation in the cell systems.</p><p>There are several limitations of this study, a major limitation being small sample sizes. In addition, while we could detect most of the testosterone metabolites, we were unable to quantify all known and intermediate metabolites, such as 6OH glucuronide, testosterone sulfate, androstanedione, and estradiol. Having this information would present a more comprehensive picture of testosterone metabolism. In addition, the in vitro enterocyte cell system that was used has not been extensively validated, although exhibited metabolic activity [43]. Moreover, restrictions in incubation times may result in incomplete reflection of in vivo metabolism that encompass sequential reactions.</p><p>In summary, we characterized UGT2B17 in first-pass effect organs, whose role in drug metabolism remains understudied and underappreciated. For example, while one study showed UGT2B17 to be one of the main isoforms responsible for clopidogrel acyl glucuronide (CAG) formation [47], another study did not include this isoform and hence concluded that UGT2B7 forms CAG [48]. In addition, TRT has recently come under scrutiny due to reports of possible increased cardiovascular events, and the risks and benefits of TRT still remain contentious among practitioners [14,49–51]. As TRT use continues to increase, elucidation of the testosterone elimination pathways is crucial for individualized dosing and optimizing treatment in precise TRT. Our data on UGT2B17 abundance will be applicable in building a PBPK model for first-pass metabolism for UGT2B17 substrates including testosterone. Extensive research and literature exist on testosterone biosynthesis pathways, but data on exogenous testosterone metabolism and elimination pathways are still lacking.</p>